Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: LRY011
MIFTS: 30

Larynx Verrucous Carcinoma

Categories: Cancer diseases, Oral diseases, Respiratory diseases
Genes Tissues Related diseases Publications Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Larynx Verrucous Carcinoma

About this section

MalaCards integrated aliases for Larynx Verrucous Carcinoma:

Name: Larynx Verrucous Carcinoma 12 15
Verrucous Carcinoma of the Larynx 12
Laryngeal Verrucous Carcinoma 73

Classifications:

MalaCards categories:
Global: Cancer diseases
Anatomical: Respiratory diseases Oral diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:3752
NCIt 50 C8188
UMLS 73 C0280328
Sources

Summaries for Larynx Verrucous Carcinoma

About this section
MalaCards based summary : Larynx Verrucous Carcinoma, also known as verrucous carcinoma of the larynx, is related to verrucous carcinoma, and has symptoms including pain and hoarseness. An important gene associated with Larynx Verrucous Carcinoma is VCL (Vinculin). The drugs Fluorouracil and Cisplatin have been mentioned in the context of this disorder. Affiliated tissues include liver, lung and lymph node, and related phenotypes are Decreased viability of wild-type and TP53 knockout cells, decreased TP53 protein expression ratio (wild-type / TP53 knockout cells) and digestive/alimentary

Sources

Related Diseases for Larynx Verrucous Carcinoma

About this section

Diseases related to Larynx Verrucous Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

# Related Disease Score Top Affiliating Genes
1 verrucous carcinoma 10.6

Sources

Symptoms & Phenotypes for Larynx Verrucous Carcinoma

About this section

UMLS symptoms related to Larynx Verrucous Carcinoma:


pain, hoarseness

GenomeRNAi Phenotypes related to Larynx Verrucous Carcinoma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability of wild-type and TP53 knockout cells, decreased TP53 protein expression ratio (wild-type / TP53 knockout cells) GR00196-A-1 8.8 ACOT13 TP53 VCL

MGI Mouse Phenotypes related to Larynx Verrucous Carcinoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 8.8 ACOT13 TP53 VCL
Sources

Drugs & Therapeutics for Larynx Verrucous Carcinoma

About this section

Drugs for Larynx Verrucous Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 196)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fluorouracil Approved Phase 3,Phase 2,Phase 1 51-21-8 3385
2
Cisplatin Approved Phase 3,Phase 2,Phase 1,Not Applicable 15663-27-1 2767 441203 84093
3
Docetaxel Approved, Investigational Phase 3,Phase 2,Phase 1 114977-28-5 148124
4
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 38904 498142
5
Cetuximab Approved Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 205923-56-4 56842117 2333
6
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
7
Fluconazole Approved, Investigational Phase 2, Phase 3 86386-73-4 3365
8
Miconazole Approved, Investigational, Vet_approved Phase 2, Phase 3,Phase 1 22916-47-8 4189
9
Cevimeline Approved Phase 3 107233-08-9 83898 25137844
10
Megestrol acetate Approved, Investigational, Vet_approved Phase 3 595-33-5 11683
11
Cobalt Approved, Experimental Phase 3 7440-48-4 104729
12
Vincristine Approved, Investigational Phase 3 57-22-7, 2068-78-2 5978
13
Bleomycin Approved, Investigational Phase 3 11056-06-7 5360373
14
leucovorin Approved Phase 3,Phase 1,Phase 2 58-05-9 6006 143
15
Methotrexate Approved Phase 3 59-05-2, 1959-05-2 126941
16
Levoleucovorin Approved, Investigational Phase 3 68538-85-2
17
Histamine Approved, Investigational Phase 3 51-45-6, 75614-87-8 774
18
Doxepin Approved, Investigational Phase 3 1668-19-5 667477 667468
19
Bevacizumab Approved, Investigational Phase 3,Phase 2,Phase 1 216974-75-3
20
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1 59-30-3 6037
21 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
22 Cola Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
23 Liver Extracts Phase 3,Phase 2,Phase 1,Early Phase 1
24 Peripheral Nervous System Agents Phase 3,Phase 2,Not Applicable
25 Anti-Infective Agents Phase 2, Phase 3,Phase 1
26 Cytochrome P-450 Enzyme Inhibitors Phase 2, Phase 3
27 Neurotransmitter Agents Phase 3,Phase 2,Not Applicable
28 Autonomic Agents Phase 3,Phase 2,Not Applicable
29 Antimetabolites Phase 3,Phase 2,Phase 1
30 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
31 Immunosuppressive Agents Phase 3,Phase 2,Phase 1,Early Phase 1
32 Immunologic Factors Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
33 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
34 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1
35 Antimitotic Agents Phase 3,Phase 2,Phase 1
36 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
37 Central Nervous System Depressants Phase 3
38 Adjuvants, Anesthesia Phase 3
39 Anesthetics, Intravenous Phase 3
40 Analgesics, Opioid Phase 3
41 Anesthetics, General Phase 3
42 Analgesics Phase 3
43 Narcotics Phase 3
44 Anesthetics Phase 3
45 Steroid Synthesis Inhibitors Phase 2, Phase 3
46 Hormone Antagonists Phase 2, Phase 3
47 Antifungal Agents Phase 2, Phase 3,Phase 1
48 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 2, Phase 3
49 Hormones Phase 2, Phase 3,Phase 1
50 Cytochrome P-450 CYP2C19 Inhibitors Phase 2, Phase 3

Interventional clinical trials:

(show top 50) (show all 127)
# Name Status NCT ID Phase Drugs
1 PET/CT Scan-Guided Watchful Waiting or Neck Dissection of Locally Advanced Lymph Node Metastases in Treating Patients Undergoing Chemotherapy and Radiation Therapy for Primary Head And Neck Cancer Unknown status NCT00720070 Phase 3
2 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
3 Acupuncture or Standard Therapy in Treating Pain and Dysfunction in Patients Who Have Undergone Neck Surgery for Head and Neck Cancer Completed NCT00090337 Phase 3
4 Fluconazole in Preventing Mucositis in Patients Undergoing Radiation Therapy for Head and Neck Cancer Completed NCT00002533 Phase 2, Phase 3 fluconazole
5 Cevimeline in Treating Patients With Dry Mouth Caused by Radiation Therapy for Head and Neck Cancer Completed NCT00017511 Phase 3 cevimeline hydrochloride
6 Study of Nutrition Regimens in Treating Patients With Cancer of the Upper Aerodigestive Tract Completed NCT00765440 Phase 3
7 Megestrol to Limit Weight Loss and Improve Quality of Life in Treating Patients With Head and Neck Cancer Completed NCT00006799 Phase 3 megestrol acetate
8 Radiation Therapy With or Without Chemotherapy in Treating Patients With Advanced Head and Neck Cancer Completed NCT00002476 Phase 3 fluorouracil;leucovorin calcium;methotrexate;vincristine sulfate
9 Doxepin Hydrochloride in Treating Oral Mucositis Pain in Patients With Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy Completed NCT01156142 Phase 3 doxepin hydrochloride
10 Radiation Therapy and Cisplatin or Panitumumab in Treating Patients With Locally Advanced Stage III or Stage IV Head and Neck Cancer Completed NCT00820248 Phase 3 cisplatin
11 Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Active, not recruiting NCT00588770 Phase 3 Carboplatin;Cisplatin;Docetaxel;Fluorouracil
12 Radiation Therapy With Cisplatin, Docetaxel, or Cetuximab After Surgery in Treating Patients With Stage III-IV Squamous Cell Head and Neck Cancer Active, not recruiting NCT01810913 Phase 2, Phase 3 cisplatin;docetaxel
13 Radiation Therapy With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer Active, not recruiting NCT00956007 Phase 3
14 CD2 Lozenges in Preventing Acute Oral Mucositis in Patients With Head and Neck Cancer Receiving Radiotherapy and Chemotherapy Withdrawn NCT01545687 Phase 3
15 Docetaxel and St. John's Wort in Treating Patients With Solid Tumors That Cannot Be Removed By Surgery Withdrawn NCT00041171 Phase 3 Hypericum perforatum;docetaxel
16 Docetaxel, Cisplatin, and Fluorouracil Followed By Cetuximab and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck Cancer Unknown status NCT00721513 Phase 2 cisplatin;docetaxel;fluorouracil
17 Cisplatin-Epinephrine Injectable Gel Plus Paclitaxel and Carboplatin in Treating Patients With Recurrent Head and Neck Cancer Unknown status NCT00022217 Phase 2 carboplatin;cisplatin-e therapeutic implant;paclitaxel
18 External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases Unknown status NCT00637637 Phase 2 indinavir sulfate;ritonavir
19 Soy Isoflavones in Preventing Head and Neck Cancer Recurrence in Patients With Stage I-IV Head and Neck Cancer Undergoing Surgery Completed NCT02007200 Phase 2 Soy Isoflavones
20 Temsirolimus With or Without Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Cancer Who Did Not Respond to Previous Therapy Completed NCT01256385 Phase 2 Temsirolimus
21 Paclitaxel and Carboplatin Before Radiation Therapy With Paclitaxel in Treating HPV-Positive Patients With Stage III-IV Oropharynx, Hypopharynx, or Larynx Cancer Completed NCT02048020 Phase 2 paclitaxel;carboplatin
22 Phase 1b Food Based Modulation of Biomarkers in Human Tissues at High-Risk for Oral Cancer. Completed NCT01469429 Phase 1, Phase 2 chemoprevention;chemoprevention
23 Saracatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer Completed NCT00513435 Phase 2 saracatinib
24 Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab Completed NCT00939627 Phase 2 sorafenib tosylate
25 Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer Completed NCT00492089 Phase 2 bevacizumab;placebo
26 Dasatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer Completed NCT00507767 Phase 2 dasatinib
27 Lapatinib Ditosylate in Treating Patients With Metastatic or Recurrent Head and Neck Cancer Completed NCT00114283 Phase 2 lapatinib ditosylate
28 S0420, Sorafenib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer Completed NCT00096512 Phase 2 sorafenib tosylate
29 Ixabepilone in Treating Patients With Metastatic or Recurrent Squamous Cell Cancer of the Head and Neck Completed NCT00033618 Phase 2 ixabepilone
30 Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer Completed NCT00101348 Phase 1, Phase 2 erlotinib hydrochloride
31 Cediranib Maleate in Treating Patients With Recurrent or Newly Diagnosed Metastatic Head and Neck Cancer Completed NCT00458978 Phase 2 Cediranib Maleate
32 Carboplatin, Paclitaxel, Cetuximab, and Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Head and Neck Squamous Cell Cancer Completed NCT01316757 Phase 2 paclitaxel;carboplatin;erlotinib hydrochloride
33 Capecitabine and Lapatinib Ditosylate in Treating Patients With Squamous Cell Cancer of the Head and Neck Completed NCT01044433 Phase 2 lapatinib ditosylate;capecitabine
34 Bortezomib With or Without Irinotecan in Treating Patients With Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Completed NCT00103259 Phase 2 bortezomib;irinotecan hydrochloride
35 SB-715992 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer Completed NCT00095628 Phase 2 ispinesib
36 Chemotherapy in Treating Patients With Solid Tumors Completed NCT00003103 Phase 1, Phase 2 docetaxel
37 High-dose ICE With Amifostine Completed NCT00003657 Phase 2 Amifostine;Carboplatin;Etoposide;Ifosfamide
38 Docetaxel in Treating Patients With Solid Tumors Completed NCT00003565 Phase 2 docetaxel
39 Oxaliplatin and Capecitabine in Treating Patients With Relapsed or Metastatic Head and Neck Cancer Completed NCT00448552 Phase 2 capecitabine;oxaliplatin
40 Cetuximab and Stereotactic Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer That Cannot Be Removed By Surgery Completed NCT00738868 Phase 2
41 Irinotecan and Cisplatin in Treating Patients With Recurrent or Metastatic Head and Neck Cancer Completed NCT00639769 Phase 2 cisplatin;irinotecan hydrochloride
42 Erlotinib, Docetaxel, and Radiation Therapy in Stage III or Stage IV Squamous Cell Carcinoma of the Head and Neck Completed NCT00720304 Phase 2 docetaxel;erlotinib hydrochloride
43 Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced Mouth Cancer Completed NCT00004901 Phase 1, Phase 2 ethynyluracil;fluorouracil;hydroxyurea
44 Epirubicin, Carboplatin, and Capecitabine in Treating Patients With Unresectable Locally Advanced, Metastatic, or Recurrent Solid Tumor Completed NCT00021047 Phase 1, Phase 2 capecitabine;carboplatin;epirubicin hydrochloride
45 Vaccine Therapy Plus Biological Therapy in Treating Adults With Metastatic Solid Tumors Completed NCT00019331 Phase 2 DetoxPC
46 Gemcitabine and Doxorubicin in Treating Patients With Recurrent or Progressive Head and Neck Cancer Completed NCT00509665 Phase 2 doxorubicin hydrochloride;gemcitabine hydrochloride
47 Everolimus, Carboplatin, and Paclitaxel in Locally Advanced Head and Neck Cancer That Cannot Be Removed by Surgery Completed NCT01333085 Phase 1, Phase 2 carboplatin;RAD001;paclitaxel
48 Paclitaxel and Cisplatin Plus Radiation Therapy Followed by Filgrastim in Treating Patients With Recurrent Head and Neck Cancer or Lung Cancer Completed NCT00021333 Phase 2 cisplatin;paclitaxel
49 Acetylcysteine Rinse in Reducing Saliva Thickness and Mucositis in Patients With Head and Neck Cancer Undergoing Radiation Therapy Active, not recruiting NCT02123511 Phase 2 acetylcysteine
50 PI3K Inhibitor BKM120 and Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer Active, not recruiting NCT01816984 Phase 1, Phase 2 PI3K inhibitor BKM120

Search NIH Clinical Center for Larynx Verrucous Carcinoma

Sources

Genetic Tests for Larynx Verrucous Carcinoma

About this section
Sources

Anatomical Context for Larynx Verrucous Carcinoma

About this section

MalaCards organs/tissues related to Larynx Verrucous Carcinoma:

41
Liver, Lung, Lymph Node, Prostate
Sources

Publications for Larynx Verrucous Carcinoma

About this section

Articles related to Larynx Verrucous Carcinoma:

(show all 32)
# Title Authors Year
1
Verrucous carcinoma of the larynx presenting as a hairy lesion. ( 24823530 )
2014
2
Verrucous carcinoma of the larynx: determining the best treatment option. ( 16626921 )
2006
3
Pathologic quiz case: laryngeal lesion in an elderly man. Verrucous carcinoma of the larynx. ( 15628892 )
2005
4
Verrucous carcinoma of the larynx: a review of 53 patients. ( 9570624 )
1998
5
Verrucous carcinoma of the larynx. ( 9596216 )
1998
6
Verrucous carcinoma of the larynx presenting as a hairy whitish tumor. ( 18493443 )
1997
7
CO2 laser surgery for verrucous carcinoma of the larynx. ( 9261788 )
1997
8
Human papillomavirus and p53 oncoprotein in verrucous carcinoma of the larynx. ( 8869607 )
1996
9
Verrucous carcinoma of the larynx. ( 7816455 )
1995
10
Outcome following radiotherapy in verrucous carcinoma of the larynx. ( 7790246 )
1995
11
Verrucous carcinoma of the larynx: role of human papillomavirus, radiation, and surgery. ( 8382761 )
1993
12
Polymerase chain reaction (PCR) identification of human papillomavirus (HPV) DNA in verrucous carcinoma of the larynx. ( 8384679 )
1993
13
Management of verrucous carcinoma of the larynx. ( 2070533 )
1991
14
Clinical and histopathological considerations for the diagnosis and treatment of verrucous carcinoma of the larynx. ( 2757559 )
1989
15
Diagnosis and management of verrucous carcinoma of the larynx. ( 3154665 )
1988
16
Verrucous carcinoma of the larynx. ( 3240742 )
1988
17
Verrucous carcinoma of the larynx. ( 3138618 )
1988
18
Verrucous carcinoma of the larynx: problems of diagnosis and treatment. ( 3343571 )
1988
19
Late response of verrucous carcinoma of the larynx to radiotherapy. ( 3356941 )
1988
20
Verrucous carcinoma of the larynx--a misnomer. ( 3662922 )
1987
21
Presence of human papillomavirus type 16 related sequences in verrucous carcinoma of the larynx. ( 3004723 )
1986
22
Verrucous carcinoma of the larynx. Possible human papillomavirus etiology. ( 2996475 )
1985
23
Verrucous carcinoma of the larynx. ( 7172465 )
1982
24
Ackerman's tumor (verrucous carcinoma) of the larynx: a clinicopathologic study of 77 cases. ( 7417957 )
1980
25
Verrucous carcinoma of the larynx. ( 926962 )
1977
26
Verrucous carcinoma of the larynx management by radiotherapy and surgery. ( 949161 )
1976
27
Verrucous carcinoma of the larynx. ( 1186399 )
1975
28
Verrucous carcinoma of the larynx. ( 1173340 )
1975
29
Toronto experience of verrucous carcinoma of the larynx. ( 1139424 )
1975
30
Verrucous carcinoma of the larynx. - A study of its pathologic anatomy. ( 1139423 )
1975
31
Verrucous carcinoma of the larynx. ( 1139425 )
1975
32
Verrucous carcinoma of the larynx. A clinical and pathologic study of 10 cases. ( 5075354 )
1972
Sources

Variations for Larynx Verrucous Carcinoma

About this section
Sources

Expression for Larynx Verrucous Carcinoma

About this section
Search GEO for disease gene expression data for Larynx Verrucous Carcinoma.
Sources

Pathways for Larynx Verrucous Carcinoma

About this section
Sources

GO Terms for Larynx Verrucous Carcinoma

About this section

Biological processes related to Larynx Verrucous Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein homotetramerization GO:0051289 8.62 ACOT13 TP53

Molecular functions related to Larynx Verrucous Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 ubiquitin protein ligase binding GO:0031625 8.62 TP53 VCL
Sources

Sources for Larynx Verrucous Carcinoma

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....